Research Solutions Announces Largest Deal: $1M Enterprise Scite Agreement with Fortune 500 Biopharma

What happened

Research Solutions announced its largest deal to date: a $1 million enterprise Scite agreement with a Fortune 500 biopharmaceutical company, highlighted in a PRNewswire release on November 11, 2026. This announcement follows the company's Q1 FY26 results (quarter ended September 30, 2025) where ARR grew 21% year-over-year to $21.3 million, and management noted strong B2B ARR growth including the previous largest Scite contract. The deal aligns with Research Solutions' strategic shift toward higher-margin Platforms revenue and AI-powered tools for scientific literature, an area the DeepValue report identifies as crucial for durable growth. However, the press release does not specify whether the $1 million is total contract value or annual recurring revenue, nor the contract term, making its true financial impact uncertain relative to total ARR. Despite this positive signal, the company remains a micro-cap with a narrow moat, concentrated supplier relationships (~45% of content costs from top three), and significant contingent earnout liabilities, so this single deal does not mitigate the structural risks previously outlined.

Implication

First, the deal validates Scite's appeal to large pharmaceutical firms, suggesting potential for further enterprise wins and supporting the company's ARR growth trajectory if the $1 million is annual recurring, which would add roughly 4.7% to total ARR. Second, if the $1 million is spread over multiple years, the annual contribution is smaller and may not significantly move the needle on revenue or profitability. Third, the deal supports the ongoing shift toward higher-margin Platforms revenue, which could improve gross margins over time, but the company still faces headwinds from open access growth and direct publisher platforms. Fourth, investors should monitor whether this deal leads to an increase in enterprise deal flow and whether the company can replicate such wins without excessive discounting or implementation costs eroding margins. Fifth, while the news is encouraging, it does not change the overall 'POTENTIAL BUY' rating; the stock still trades at a significant DCF discount but execution risks and industry challenges remain, so position sizing should remain conservative.

Thesis delta

The thesis shifts marginally positive with this record enterprise deal, providing concrete evidence of Scite's product-market fit in large biopharma and supporting the narrative of accelerating enterprise demand. However, the deal's size is relatively small compared to total ARR and the announcement lacks critical details on contract duration, so the overall investment case is not fundamentally altered. The 'POTENTIAL BUY' rating remains, with the same key risk factors—supplier concentration, industry disruption, and earnout obligations—still dominant.